Cargando…
“Locked” cancer cells are more sensitive to chemotherapy
The treatment of metastatic cancer is a great challenging issue throughout the world. Conventional chemotherapy can kill the cancer cells and, whereas, would exacerbate the metastasis and induce drug resistance. Here, a new combinatorial treatment strategy of metastatic cancer was probed via subsequ...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley & Sons, Inc.
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6584094/ https://www.ncbi.nlm.nih.gov/pubmed/31249880 http://dx.doi.org/10.1002/btm2.10130 |
_version_ | 1783428474909753344 |
---|---|
author | Lyu, Yaqi Xiao, Qingqing Li, Yi Wu, Yubing He, Wei Yin, Lifang |
author_facet | Lyu, Yaqi Xiao, Qingqing Li, Yi Wu, Yubing He, Wei Yin, Lifang |
author_sort | Lyu, Yaqi |
collection | PubMed |
description | The treatment of metastatic cancer is a great challenging issue throughout the world. Conventional chemotherapy can kill the cancer cells and, whereas, would exacerbate the metastasis and induce drug resistance. Here, a new combinatorial treatment strategy of metastatic cancer was probed via subsequentially dosing dual nanomedicines, marimastat‐loaded thermosensitive liposomes (MATT‐LTSLs) and paclitaxel nanocrystals (PTX‐Ns), via intravenous and intratumoral injection. First, the metastasis was blocked and cancer cells were locked in the tumor microenvironment (TME) by delivering the matrix metalloproteinase (MMP) inhibitor, MATT, to the tumor with LTSLs, downregulating the MMPs by threefold and reducing the degradation of the extracellular matrix. And then, the “locked” cancer cells were efficiently killed via intratumoral injection of the other cytotoxic nanomedicine, PTX‐Ns, along with no metastasis and 100% inhibition of tumor growth. This work highlights the importance of the TME's integrity in the chemotherapy duration. We believe this is a generalized strategy for cancer treatment and has potential guidance for the clinical administration. |
format | Online Article Text |
id | pubmed-6584094 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | John Wiley & Sons, Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-65840942019-06-27 “Locked” cancer cells are more sensitive to chemotherapy Lyu, Yaqi Xiao, Qingqing Li, Yi Wu, Yubing He, Wei Yin, Lifang Bioeng Transl Med Research Reports The treatment of metastatic cancer is a great challenging issue throughout the world. Conventional chemotherapy can kill the cancer cells and, whereas, would exacerbate the metastasis and induce drug resistance. Here, a new combinatorial treatment strategy of metastatic cancer was probed via subsequentially dosing dual nanomedicines, marimastat‐loaded thermosensitive liposomes (MATT‐LTSLs) and paclitaxel nanocrystals (PTX‐Ns), via intravenous and intratumoral injection. First, the metastasis was blocked and cancer cells were locked in the tumor microenvironment (TME) by delivering the matrix metalloproteinase (MMP) inhibitor, MATT, to the tumor with LTSLs, downregulating the MMPs by threefold and reducing the degradation of the extracellular matrix. And then, the “locked” cancer cells were efficiently killed via intratumoral injection of the other cytotoxic nanomedicine, PTX‐Ns, along with no metastasis and 100% inhibition of tumor growth. This work highlights the importance of the TME's integrity in the chemotherapy duration. We believe this is a generalized strategy for cancer treatment and has potential guidance for the clinical administration. John Wiley & Sons, Inc. 2019-06-10 /pmc/articles/PMC6584094/ /pubmed/31249880 http://dx.doi.org/10.1002/btm2.10130 Text en © 2019 The Authors. Bioengineering & Translational Medicine published by Wiley Periodicals, Inc. on behalf of The American Institute of Chemical Engineers. This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Research Reports Lyu, Yaqi Xiao, Qingqing Li, Yi Wu, Yubing He, Wei Yin, Lifang “Locked” cancer cells are more sensitive to chemotherapy |
title | “Locked” cancer cells are more sensitive to chemotherapy |
title_full | “Locked” cancer cells are more sensitive to chemotherapy |
title_fullStr | “Locked” cancer cells are more sensitive to chemotherapy |
title_full_unstemmed | “Locked” cancer cells are more sensitive to chemotherapy |
title_short | “Locked” cancer cells are more sensitive to chemotherapy |
title_sort | “locked” cancer cells are more sensitive to chemotherapy |
topic | Research Reports |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6584094/ https://www.ncbi.nlm.nih.gov/pubmed/31249880 http://dx.doi.org/10.1002/btm2.10130 |
work_keys_str_mv | AT lyuyaqi lockedcancercellsaremoresensitivetochemotherapy AT xiaoqingqing lockedcancercellsaremoresensitivetochemotherapy AT liyi lockedcancercellsaremoresensitivetochemotherapy AT wuyubing lockedcancercellsaremoresensitivetochemotherapy AT hewei lockedcancercellsaremoresensitivetochemotherapy AT yinlifang lockedcancercellsaremoresensitivetochemotherapy |